生物主动脉瓣植入后衰败:经导管瓣膜植入的挑战
本文回顾了外科主动脉瓣置换(SAVR)60年来生物瓣植入后结构性衰败的挑战,指出TAVI瓣膜因部署方式固有难题可能面临更严重的衰败问题,需借鉴SAVR经验来优化TAVI技术,但两者衰败差异尚待明确。
要点
- 生物瓣植入后10-15年常发生结构性衰败,可能导致再次手术。
- TAVI瓣膜因部署方式固有挑战,其植入后衰败问题日益受关注。
- TAVI与SAVR术后瓣膜衰败差异尚未明确,需借鉴SAVR经验优化TAVI。
核心结论
- TAVI瓣膜因部署方式固有挑战可能面临结构性衰败,需借鉴SAVR经验优化技术,但两者衰败差异尚待明确。
研究设计与样本
- 本文为综述,基于SAVR 60年经验和TAVI现状,讨论生物瓣植入后衰败问题。
主要发现
- 生物瓣功能通常在植入后10-15年下降,结构性衰败常需再次手术。
- TAVI瓣膜因部署方式固有挑战,其结构性衰败问题日益受关注。
- TAVI与SAVR术后瓣膜衰败的影响差异尚未明确。
临床怎么用
- 在扩大TAVI适应症时,应借鉴SAVR 60年经验中的潜在缺陷和注意事项来优化技术。
局限性
- 本文为综述,未提供原始研究数据,TAVI与SAVR瓣膜衰败差异尚未明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Surgical aortic valve replacement (SAVR) is highly effective and can be achieved with relatively low risk in patients with severe aortic stenosis. Bioprostheses have been used most frequently during the past 60 years. However, the function of biological valves usually declines after 10-15 years from implant when structural valve degeneration occurs often mandating a reoperation once valve dysfunction becomes haemodynamically significant. Known for many years by surgeons and cardiologists taking care of patients with SAVR, the issue of postimplant structural valve degeneration has been recently highlighted also in patients with transcatheter aortic valve implant (TAVI). There is growing concern that TAVI valves exhibit structural valve degeneration due to inherent challenges of the deployment mode. The impact on postimplant degeneration of TAVI valves compared to SAVR has still to be understood and defined. Based on the ongoing process of expanding TAVI indications, several potential shortcomings and caveats, learned during the last 60 years of SAVR experience, should be taken into consideration to refine this technique.
引用
- Bidar E, Folliguet T, Kluin J, et al. Postimplant biological aortic prosthesis degeneration: challenges in transcatheter valve implants. Eur J Cardiothorac Surg. 2019. PMID: 30541101. doi:10.1093/ejcts/ezy391
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。